Skip to main content
IONS
NASDAQ Life Sciences

Ionis Cuts TRYNGOLZA 2026 Sales Guidance to ~$50M as sHTG Launch Lags

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$37
Mkt Cap
$6.551B
52W Low
$38.305
52W High
$86.74
52W Position info
3.4% below low
Off High info
57% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

IONS is trading near its 52-week low of $38.305 (3.4% below the low).

Summary

Ionis reported Q3 2026 revenue of $243 million and a $0.66 per-share loss, but cut 2026 TRYNGOLZA sales guidance to about $50 million from $100-110 million as the sHTG launch ramps more slowly than planned. Total revenue, operating loss and cash guidance were reaffirmed.


Key Events · Earnings and Guidance · IONS

  • TRYNGOLZA Guidance Cut

    Full-year 2026 TRYNGOLZA net product sales guidance lowered to approximately $50 million from $100-110 million, after $9 million of U.S. net sales in Q3 and $41 million in the first nine months.

  • Q3 Revenue and Loss

    Total revenue was $243 million versus $157 million a year ago; net loss was $110 million, or $0.66 per share, on 166 million shares.

  • DAWNZERA and Total Guidance Reaffirmed

    DAWNZERA posted $37 million of Q3 net sales and remains on track for $110-120 million for 2026; total revenue of $875-900 million, non-GAAP operating loss of $425-475 million and cash above $1.6 billion were all reaffirmed.

  • Cash Falls After Convertible Repayment

    Cash, cash equivalents and short-term investments were $1.9 billion at September 30, 2026, down from $2.7 billion at December 31, 2025, primarily on repayment of the 0% convertible notes due April 2026.


Analysis · IONS · Life Sciences

The headline number is the TRYNGOLZA cut: full-year 2026 product sales guidance drops from $100-110 million to roughly $50 million after only $9 million of U.S. net sales in the third quarter. That is the company's first launch in a large indication, so a slower-than-expected ramp pushes out the revenue curve investors were underwriting. The rest of the quarter is steadier — total revenue of $243 million versus $157 million a year ago, DAWNZERA tracking its $110-120 million guidance, and total revenue, non-GAAP operating loss and cash guidance all reaffirmed. With $1.9 billion of cash and short-term investments, funding is not the near-term issue; the question is whether TRYNGOLZA's sHTG trajectory is a launch-timing problem or a demand problem.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IONS was trading at $37.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $38.31 to $86.74. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IONS - Latest Insights

IONS
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $37.00
Real-time Price: $35.00 info
Change: -$2.00 (-5%) info
Market Cap: $6.551B info
IONS
Oct 23, 2026, 1:41 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $42.93
Real-time Price: $35.00 info
Change: -$7.93 (-18%) info
Market Cap: $6.551B info
IONS
Oct 20, 2026, 9:20 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $45.20
Real-time Price: $35.00 info
Change: -$10.20 (-23%) info
Market Cap: $6.551B info
IONS
Oct 16, 2026, 6:45 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $43.56
Real-time Price: $35.00 info
Change: -$8.56 (-20%) info
Market Cap: $6.551B info
IONS
Sep 23, 2026, 1:00 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $45.75
Real-time Price: $35.00 info
Change: -$10.75 (-23%) info
Market Cap: $6.551B info